The National Healthcare Security Administration (NHSA) of China, in collaboration with the Supreme People’s Court, Supreme People’s Procuratorate, Ministry of Public Security, Ministry of Finance, and National Health Commission, has jointly issued the “2024 Special Work Plan for the Rectification of Illegal and Non-compliant Issues Related to Medical Insurance Funds.” The directive calls for an in-depth special rectification across all provinces, cities, and autonomous regions to address legal and compliance issues within the medical insurance sector and to rigorously combat fraud.
The plan’s special rectification efforts will concentrate on fraudulent activities such as counterfeit diagnosis and treatment, fictitious drug procurement, and the resale of drugs listed in the National Reimbursement Drug List (NRDL). The focus will be on key medications and consumables that have seen substantial use of medical insurance funds and have exhibited unusual fluctuations, with dynamic monitoring of fund usage being implemented. Additionally, the plan will emphasize the integration of rectification and treatment, requiring a comprehensive self-inspection and self-correction in areas such as orthopedics, hemodialysis, endocardial care, examination, testing, and rehabilitation therapy. – Flcube.com
